Overview
Our extensive Hatch-Waxman litigation practice and successful practice in post-grant PTO proceedings, combined with our deep technical expertise in biotechnology, uniquely positions us to develop and implement effective IP strategies for biosimilars. This industry-specific expertise is backed by one of the largest and most experienced biotechnology groups in IP law, with more than 75 attorneys and scientists representing clients in all stages of their business and technology development, as well a talented litigation group adept in all aspects of biotechnology IP law.
Biosimilars Pathway Bench Strength:
- Up-to-date knowledge of biosimilars legislation
- IP litigators with numerous trial and appellate successes
- Extensive Hatch-Waxman litigation experience
- Successful Post-Grant PTO practice on behalf of patent owners and petitioners
- More than 20 attorneys with PhD’s in the life sciences
- Extensive experience in biologics patent prosecution
- Licensing and other transactional experience related to biologics
Latest Updates and News
Blogs
Nov 2026Rethinking Interchangeability: Proposed Legislation for Biosimilars in Congress
Key Takeaway: Proposed federal legislation would eliminate the separate regulatory requirements for interchangeable biosimilars, potentially making it easier for biosimilars to compete with reference biologics. Congress is considering legislation aimed...
Blogs
Nov 2026FDA’s New Neuroscience Initiative Highlights the Importance of Early, Adaptive Patent Strategy
Key Takeaway: The FDA’s new neuroscience initiative is designed to accelerate a new wave of biotechnology innovation, and with it, new opportunities for intellectual property protection. For companies developing neuroscience...
Blogs
Apr 2026FDA Issues Recommendations for the Development of Individualized Therapies for Patients With Ultra-Rare Diseases
Key Takeaway: The FDA is developing a “plausible mechanism framework” to facilitate approval of individualized therapies for the treatment of rare genetic diseases that currently face approval challenges. As discussed previously...
Blogs
Mar 2026New FDA Guidance Allows Biosimilar Applicants to Use Data From Outside the U.S. To Accelerate Their Approval in the U.S.
Key Takeaway: New FDA guidance released on February 23, 2026, and March 9, 2026, signals a continued shift toward regulatory flexibility aimed at accelerating approval of biosimilar treatments for rare...
Blogs
Dec 2025Life Science Considerations on the USPTO’s New Guidelines for AI-Assisted Inventorship
On November 26, 2025, the United States Patent and Trademark Office (USPTO) issued revised guidelines for determining inventorship of AI-assisted inventions,[1] which is a significant development in life science innovations,...
Blogs
Dec 2025USPTO’s Automated Search Pilot: Through a Biotech Lens
In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “Artificial Intelligence Search Automated Pilot Program,” or ASAP!, an initiative to identify potential prior art using artificial intelligence...